Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
R&D Expense Growth
12.75%
Quarterly · Period ending:
LCTX R&D Expense Growth
Latest reported12.75%period ending
Latest reported12.75%period ending
LCTX Quarterly R&D Growth (QoQ) (0.00% → 12.75%)
Latest values, visible window
High-resolution chart · PNG
LCTX r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -2.1661% | |
| -18.0305% | |
| -20.2242% | |
| -8.9354% | |
| 2.2218% | |
| -17.3183% | |
| -44.974% | |
| 81.8182% | |
| 57.1429% | |
| 0% | |
| 50% | |
| -33.3333% | |
| 0% | |
| 28.5714% | |
| -12.5% | |
| 100% | |
| -20% | |
| 25% | |
| 0% | |
| 0% | |
| 0% | |
| -100% | |
| -66.6667% | |
| 50% | |
| -20% | |
| 66.6667% | |
| 0% | |
| 200% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |